The human rights and patient consequences of Gilead's proposed anti-diversion policies in its tiered-pricing and licensing programs for sofosbuvir, listed by MSF, are quite specific and substance-focused... Gilead's response on the other hand is vague and process oriented - it promises consultation with no specifics in terms of the concerns raised.